🩺 A new drug for schizophrenia, called Cobenfy, has been developed by US pharma giant Bristol Myers Squibb, and approved September 27. The drug works differently from existing treatments, targeting the so-called cholinergic receptors, not the dopamine receptors.
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
"UK HEIs that have not yet explored the potential implications of the increasing implementation of digital services tax for cross-border online education activities should start doing so."
If you’ve ever had to complete a UK tax return, you’re probably familiar with old government adverts featuring Adam Hart-Davis and the slogan “tax doesn’t have to be taxing.” Having spent a fair…
🩺 "‘The involvement of the central nervous system in the pathophysiology of fatigue in post-COVID syndrome paves the way for the use of non-invasive brain stimulation techniques to alleviate fatigue in these patients,’ the researchers conclude."
Mental and physical fatigue look different.
🩺 The drug KarXT, approved by the US FDA, is the first medication for schizophrenia in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.
🩺 Newly Found Genetic Mutation Linked to Early-Onset Parkinson’s
🩺 The drug KarXT, approved by the US FDA, is the first medication for schizophrenia in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.